Literature DB >> 2830189

Individual responses to converting enzyme inhibitors and calcium antagonists.

J Bidiville1, J Nussberger, G Waeber, M Porchet, B Waeber, H R Brunner.   

Abstract

This study was designed to assess whether the acute blood pressure response of an individual hypertensive patient to a calcium antagonist or an angiotensin converting enzyme (ACE) inhibitor is a good predictor of the long-term efficacy of these drug classes in this particular patient. The concept that good responses to ACE inhibitors and calcium antagonists may be mutually exclusive was also tested. Sixteen patients were included in a randomized crossover trial of enalapril, 20 mg daily, and diltiazem, 120 mg daily, for 6 weeks each. Blood pressure was measured by ambulatory blood pressure recording. During the washout phase, the acute effect of nifedipine, 10 mg p.o., and enalaprilat, 5 mg i.v., was evaluated. Nifedipine and enalaprilat reduced blood pressure equally well. The long-term blood pressure reduction induced by enalapril and diltiazem was similar. The acute blood pressure response to a given drug was not a good predictor of the result obtained with long-term therapy. No age dependency of the antihypertensive effect of either drug class was apparent. There was no evidence that a good response to one drug excluded a similarly good response to the other.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2830189     DOI: 10.1161/01.hyp.11.2.166

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

Review 1.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

2.  Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors:  Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

3.  The description and prediction of antihypertensive drug response: an individualised approach.

Authors:  R Donnelly; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

4.  Predicting changes in hypertension control using electronic health records from a chronic disease management program.

Authors:  Jimeng Sun; Candace D McNaughton; Ping Zhang; Adam Perer; Aris Gkoulalas-Divanis; Joshua C Denny; Jacqueline Kirby; Thomas Lasko; Alexander Saip; Bradley A Malin
Journal:  J Am Med Inform Assoc       Date:  2013-09-17       Impact factor: 4.497

5.  Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.

Authors:  G Waeber; M Burnier; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

7.  Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.

Authors:  Yan Gong; Zhiying Wang; Amber L Beitelshees; Caitrin W McDonough; Taimour Y Langaee; Karen Hall; Siegfried O F Schmidt; Robert W Curry; John G Gums; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Hypertension       Date:  2016-01-04       Impact factor: 10.190

8.  The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.

Authors:  Gary L Schwartz; Kent Bailey; Arlene B Chapman; Eric Boerwinkle; Stephen T Turner
Journal:  Am J Hypertens       Date:  2013-04-16       Impact factor: 2.689

9.  Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.

Authors:  Kamel A Gharaibeh; Stephen T Turner; Abdurrahman M Hamadah; Arlene B Chapman; Rhonda M Cooper-Dehoff; Julie A Johnson; John G Gums; Kent R Bailey; Gary L Schwartz
Journal:  Am J Hypertens       Date:  2016-06-30       Impact factor: 2.689

10.  Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors.

Authors:  Y Y Chen; D Liu; P Zhang; J C Zhong; C J Zhang; S L Wu; Y Q Zhang; G Z Liu; M He; L J Jin; H M Yu
Journal:  J Hum Hypertens       Date:  2016-04-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.